Elastrin Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Elastrin Therapeutics's estimated annual revenue is currently $2.3M per year.
- Elastrin Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Elastrin Therapeutics has 15 Employees.
- Elastrin Therapeutics grew their employee count by 50% last year.
Elastrin Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | CSO | Reveal Email/Phone |
Elastrin Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Elastrin Therapeutics?
Elastrin Therapeutics is a biotech startup with technologies to restore hardened and damaged arteries & tissue by targeting the elastic fiber that makes them work. Our mission is to improve quality of life by restoring damaged hardened tissue to healthy resilience. We have proof of mechanism for reversing hardening of arteries and inflammatory tissue damage in arterial, CKD and lung disease models.
keywords:N/AN/A
Total Funding
15
Number of Employees
$2.3M
Revenue (est)
50%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Elastrin Therapeutics News
Naren Vyavahare over a 20-year period, and led by CEO Matthias Breugelmans, Elastrin Therapeutics is a biotech company developing therapies to...
Other investors in the round include Starbloom Capital and SC Launch. Elastrin Therapeutics was founded in 2018 as a spinout from Clemson...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 15 | 15% | $200M |
#2 | $0.6M | 15 | 0% | $4.3M |
#3 | $1.1M | 15 | 7% | N/A |
#4 | $1.3M | 15 | N/A | N/A |
#5 | $1.3M | 15 | N/A | N/A |